Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mreg_UKR in living-donor renal transplant recipients
NCT02085629Phase 2Terminated
- Sponsor
- University of Regensburg
- Start
- Jul 2014
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 2, open-label trial of Mreg_UKR in kidney failure (ESRD), sponsored by University of Regensburg. Primary endpoint: Biopsy-Confirmed Acute Rejection at 60 weeks. Started Jul 2014; status: terminated.
02
Drugs
Mreg_UKR
03
Conditions
kidney failure (ESRD)
Beyond the preview
Go deeper on NCT02085629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02085629.